The Traderszone Network

Published in TZ Latest News 18 February, 2015 by The TZ Newswire Staff

Regeneron drug tops rivals in some vision loss cases

Regeneron’s Eylea bested Roche’s Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.